Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The prognosis of gliomas with different molecular subtypes in the era of intensity-modulated radiation therapy (IMRT).

Aging - 8 Aug 2023

Zhong Qiulu, Luo Danjing, Chen Da, Li Xiangde, Du Qinghua, Liang Qianfu, Li Jian, Zhu Xiaodong

Abstract excerpt

PURPOSE: This study aimed to evaluate the prognosis of glioma patients with different molecular subtypes of who treated with intensity-modulated radiation therapy (IMRT). METHODS: We collected 45 glioma patients treated in our hospital between January 2017 and December 2020. All enrolled patients received postoperative IMRT and were divided into two groups based on the Isocitrate dehydrogenase (IDH status)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Chromosome Aberrations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 37556350
DOI: 10.18632/aging.204942
PMCID: PMC10457046

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The prognosis of gliomas with different molecular subtypes in the era of intensity-modulated radiation therapy (IMRT).PMID 37556350Read ↗

Clinical Characteristics, Treatment Outcomes, And Genetic Alterations of Radiation-Induced GliomasSemantic proximity Read ↗

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.Semantic proximity Read ↗

Real-World Survival Outcomes After (Chemo)radiotherapy for WHO 2021-Classified Gliomas: A Multicenter Analysis of Clinical, Treatment-Related, Dosimetric, and Hematologic Prognostic FactorsSemantic proximity Read ↗

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsSemantic proximity Read ↗

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?Semantic proximity Read ↗

The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?Semantic proximity Read ↗

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Semantic proximity Read ↗

[Molecular subtype-driven surgical concepts and clinical application in gliomas].Semantic proximity Read ↗

IDH1R132H mutation increases radiotherapy efficacy and a 4-gene radiotherapy-related signature of WHO grade 4 gliomas.Semantic proximity Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

Survival Impact of Isocitrate Dehydrogenase (IDH)-Wildtype Histological Versus Molecular Glioblastoma: A Propensity Score-Matched AnalysisSemantic proximity Read ↗

IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.